Parkinson’s disease (PD) is characterized by the loss of dopamine-producing neurons in the nigrostriatal system. Numerous researchers in the past have attempted to track the progression of dopaminergic depletion in PD. We applied a quantitative non-invasive PET imaging technique to follow this degeneration process in an MPTP-induced mouse model of PD. The VMAT2 ligand 18F-DTBZ (AV-133) was used as a radioactive tracer in our imaging experiments to monitor the changes of the dopaminergic system. Intraperitoneal administrations of MPTP (a neurotoxin) were delivered to mice at regular intervals to induce lesions consistent with PD. Our results indicate a significant decline in the levels of striatal dopamine and its metabolites (DOPAC and HVA) following MPTP treatment as determined by HPLC method. Images obtained by positron emission tomography revealed uptake of 18F-DTBZ analog in the mouse striatum. However, reduction in radioligand binding was evident in the striatum of MPTP lesioned animals as compared with the control group. Immunohistochemical analysis further confirmed PET imaging results and indicated the progressive loss of dopaminergic neurons in treated animals compared with the control counterparts. In conclusion, our findings suggest that MPTP induced PD in mouse model is appropriate to follow the degeneration of dopaminergic system and that 18F-DTBZ analog is a potentially sensitive radiotracer that can used to diagnose changes associated with PD by PET imaging modality.
Citation: Toomey JS, Bhatia S, Moon LT, Orchard EA, Tainter KH, Lokitz SJ, et al. (2012) PET Imaging a MPTP-Induced Mouse Model of Parkinson’s Disease Using the Fluoropropyl-Dihydrotetrabenazine Analog [18F]-DTBZ (AV-133). PLoS ONE 7(6): e39041. https://doi.org/10.1371/journal.pone.0039041
Editor: Chin-Tu Chen, The University of Chicago, United States of America
Received: December 16, 2011; Accepted: May 16, 2012; Published: June 18, 2012
Copyright: © 2012 Toomey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Louisiana Gene Therapy Research Consortium and the Biomedical Research Institute of Northwest Louisiana. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors declare that they have no conflicts of interest.
According to the Parkinson’s disease Foundation, Parkinson’s disease (PD) is estimated to currently affect as many as 1 million Americans; about 50 to 60,000 Americans are diagnosed with the disease every year. The causes of PD are still unknown; but genetics may be a contributing factor and environmental toxins may also play a role . Investigators have used experimental models of PD to provide insights into the mechanisms responsible for the loss of dopaminergic neurons in PD . The chemically induced mouse model of PD using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been widely used in developing and evaluating new treatments of PD . MPTP is capable of causing clinical signs found in PD by producing a reliable and reproducible lesion of the substantia nigra.
Non-invasive imaging studies using positron emission tomography (PET) have been useful for monitoring the loss of dopaminergic neurons in PD patients and animal models with the radiotracer 6-[18F]-fluoro-L-DOPA (18F-DOPA). However, 18F-DOPA is rapidly metabolized in the periphery following intravenous injection, limiting its utility . Thus, alternative radiotracers have been investigated. Dihydrotetrabenazine (DTBZ) analogs have been investigated as radiotracers for the vesicular monoamine transporter (VMAT2) , expressed in the central nervous system (CNS) , as well as in pancreatic beta cells , . VMAT2 plays a role in vesicular packaging and storage of monoamine neurotransmitters in the synapses of the brain, where it is responsible for the movement of the monoamines (dopamine, serotonin, and norepinephrine) from the cytosol into the vesicular lumen . VMAT2 is highly expressed in the striatum, hypothalamus, substantia nigra, and hippocampus, with lower levels in the cerebellum and occipital cortex , . Decreases of VMAT2 levels have been associated with PD , .
In models of PD, 3H-radiolabeled VMAT2 ligand analogs have demonstrated loss of binding and have provided an accurate assessment of monoamine neuronal loss. Non-invasive imaging of CNS receptors in particular requires high specific activity ligands. Using the positron emitter 11C, the [11C](+)-DTBZ radiotracer has been useful for imaging changes in numbers of dopaminergic neurons by PET . However, the relatively short half-life of 11C (20 min) and manufacturing constraints has limited this radiotracer from widespread clinical use. More recently, an 18F-radiolabeled DTBZ analog has been developed, providing a radiotracer with a longer half-life (110 min) and the potential for clinical use , . While this analog is currently being evaluated in clinical trials  and in a rat model of PD , the capability of this radiotracer has not been examined using a mouse model in vivo. The purpose of this study was to evaluate the MPTP mouse model of PD using 18F-DTBZ specific for VMAT2 to follow loss of dopaminergic neurons. This non-invasive imaging approach can add value to the MPTP mouse model and can assist in the development of new treatments for PD.
Materials and Methods
All animals used in this study received humane care based on guidelines set by the American Veterinary Association as well as in accordance with the Guide for the Care and Use of Laboratory Animals (Institute for Laboratory Animal Research, Washington, DC). The experimental protocols involving live animals were reviewed and approved by the Institutional Animal Care and Use Committee of LSU Health Sciences Center at Shreveport (protocol P-10-028). All efforts were made to minimize animal suffering, to reduce the number of animals used and to utilize alternatives to in vivo techniques, if available.
Male C57BL/6NCrl mice between 8 and 10 weeks of age were obtained from the Jackson Laboratory (Bar Harbor, ME).
At the start of each dosing, MPTP obtained from Sigma Aldrich (St. Louis, MO) was reconstituted with sterile saline solution to a concentration of 5 mg/ml. On Day 1, mice in one of three dose groups were given four IP doses (2 hours apart) of saline, MPTP at 15 mg/kg or MPTP at 17 mg/kg and kept warm throughout the dosing period. Each mouse was euthanized by CO2 asphyxiation on Day 15. For each animal, the brain was harvested and the striatum was extracted, snap frozen with liquid N2, and stored at −80°C.
Brain sections were homogenized in 200 – 750 µL of 0.1 M trichloroacetic acid (TCA), which contained 10−2 M sodium acetate, 10−4 M EDTA and 10.5% methanol (pH 3.8) using a tissue dismembrator (Fisher Scientific; Pittsburgh, PA). Samples were spun in a microcentrifuge at 10,000×g for 20 minutes and analyzed for biogenic monoamines and/or amino acids.
Analysis of Biogenic Amines
Samples of brain striatum were processed and analyzed at the Neurochemistry Core lab at Vanderbilt University (Nashville TN). Biogenic amines were determined based on a specific HPLC assay as previously described  utilizing an Antec Decade II (oxidation: 0.5) electrochemical detector operated at 33°C. Samples of the supernatant (20 µL) were injected using a Water 717+ autosampler onto a Phenomenex Nucleosil (5 μ, 100 A) C18 HPLC column (150×4.60 mm). Biogenic amines were eluted with a mobile phase consisting of 89.5% 0.1 M TCA, 10−2 M sodium acetate, 10−4 M EDTA, and 10.5% methanol (pH 3.8). Solvent was delivered at 0.8 mL/min using a Waters 515 HPLC pump. Using this HPLC solvent, the following biogenic amines eluted in the following order: noradrenaline, adrenaline, DOPAC, Dopamine, 5-HIAA, HVA, 5-HT, and 3-MT. Concentrations are expressed as nanograms per milligram of total protein.
Total protein concentration of the brain extracts was determined using a BCA Protein Assay Kit purchased from Pierce Chemical Company (Rockford, IL). The frozen pellets were allowed to thaw and reconstituted in a volume of 0.5 N HCl equal to that previously used for tissue homogenization. A 100 µL aliquot of this solution was combined with 2 mL of color reagent and allowed to develop for 2 hours. A BSA standard curve was run at the same time spanning the concentration range of 20 – 2000 µg/mL. Absorbances of standards and samples were measured at 562 nm.
Brain samples were stained for detection of tyrosine hydroxylase (TH) to visualize the effect of MPTP treatment. Samples of brain striatum were post-fixed in 10% buffered formalin (48 h, 4°C). The fixed tissue samples were dehydrated with gradated alcohols, cleared with xylene, and infiltrated with paraffin overnight. Paraffin-embedded tissue samples were then cut into 5 µm-thick sections, which were mounted on slides, deparaffinized with xylene, and rehydrated in gradated alcohols prior to staining. Sections were processed in a 10 mm citrate buffer for enhancement of antigen retrieval. After blocking with 10% donkey serum for 1 h, an anti-TH antibody (Sigma) was applied to the sections for overnight incubation at 4°C. For immunofluorescence staining, a Texas Red conjugated secondary antibody was used for fluorescence detection. For immunohistochemistry staining, a horseradish peroxidase conjugated secondary antibody was used followed by 3,3′ diaminobenzidine processing.
The [18F]-DTBZ radiotracer (AV133) was prepared from aqueous [18F]-fluoride as previously described . Radiochemical purity and specific activity of each synthesis were determined by analytical HPLC. PET studies were performed using a FLEX Triumph™ multi-modality pre-clinical platform (Gamma-Medica Ideas, Northridge, CA) combining three different imaging modalities (PET, SPECT, and CT) in a single platform. In brief, the system features 2×2×12 mm3 LYSO and LGSO crystals assembled in phoswich pairs, read out by Avalanche PhotoDiode (APD) detectors, and arranged for a 7.5 cm transaxial field-of-view. For the imaging studies, the mice were injected in the tail vein with 300 µCi of [18F]-DTBZ. After 60 minutes, the animals were anesthetized with isoflurane and image data was acquired for 15 minutes. PET images were reconstructed by using an iterative reconstruction technique. The reconstructed pixel size was 0.25×0.25×1.175 mm, which produces voxels of 0.07 mm3.
The purpose of the CT imaging was alignment of the PET data for registration to a brain atlas . CT images were acquired immediately after PET imaging while the animals were still under anesthesia. CT images were acquired with 80 kVp voltage with optimal current, for 256 projections over 360 degrees. Reconstructed images were either 512×512×512 voxels with a voxel size of 0.1 mm3.
Initially, one CT scan from a normal control animal was manually reoriented so that bregma and lambda were in the same slice plane and vertically colinear, and the intra-aural canals were in the same plane and horizontally collinear. This position is easily related to atlas coordinates, which commonly reference distances from bregma, the midline, and the intra-aural line . The CT for each subsequent animal was then registered to the first CT using the normalized mutual information algorithm available in SPM2, a statistical image processing utility developed for Matlab (Mathworks Inc., Natick, MA). Finally, PET images were registered to their corresponding CT and resliced in the new orientation having cubic voxel dimensions of 0.2 mm and an origin located at the bregma. Images were then cropped to include only the skull and brain and intensity normalized so that the minimum voxel value was 0 and the maximum voxel value was 1. The methods used for orienting the images were previously developed for use with imaging PD models in rats . Regions of interest for the striatum were identified in the PET images of normal control animals in eleven slices of the image centered on the slice containing bregma, and individual voxels were measured within a circle of radius 10 voxels for both left and right striatum. The total number of cerebellar measurements for each image was 1246 voxels (178 voxels/slice). For comparison with striatum values, regions of the cerebellum were also measured in eleven image slices, using circular regions of 10 voxels radius. The total number of cerebellar measurements for each image was 979 voxels (89 voxels/slice). For both striatal and cerebellar measurements, the mean voxel values for each slice were first determined, and then the means and standard deviations of all slices from each image were obtained. The groups of striatal and cerebellar slices from each animal were subsequently compared using one-way ANOVA followed by pair-wise Tukey’s post-hoc test. The statistics were calculated by the GraphPad InStat version 3.2 software (GraphPad Software, Inc., La Jolla, CA). A P value less than 0.05 was considered statistically significant.
To implement a mouse model of PD using the neurotoxin MPTP safely and successfully, it is critical to be consistent with MPTP injection route, regimen and mice including strain, vendor, gender, age, and body weight . All of these factors have a significant impact on the sensitivity and reproducibility of the lesion caused by MPTP administration and the degree of dopaminergic neurodegeneration. For these studies, we used C57BL/6NCrl mice between 8 and 10 weeks of age from the Jackson Laboratory. On Day 1, each mouse was administered four IP doses (approximately 2 hours apart) of saline (Group 1) or MPTP (Groups 2 and 3). Animals in Group 2 were given 15 mg/kg doses and animals in Group 3 were given 17 mg/kg doses. The animals in Groups 2 and 3 were noted to be hypoactive during the first 24 hours after dosing with MPTP. These clinical signs resolved and all animals were clinically normal throughout the rest of the study. One Group 3 animal died acutely during the second IP dosing procedure. Due to the circumstances of this animal’s death, it is suspected that the death was secondary to an IP injection error and not directly related to MPTP toxicity. Group 1 (control) animals showed no abnormal clinical signs throughout the course of the study. No treatment-related morbidity or mortality was reported during the study. Body weights for all animals were obtained on days 1 and 15. Body weights were averaged for each group and the percent of body weight gained over the course of the study was determined for each group. Group 1 animals gained 8.4% (2.1±0.7 g) of their day 1 body weight over the course of the study, from 24.4±1.3 g to 26.5±1.6 g. Group 2 animals gained 7.2% (1.7±1.1 g), from 22.9 g±1.3 g to 24.5±2.1 g, and Group 3 animals gained 6.8% (1.6±0.5 g), from 23.0 g±2.1 g to 24.6±2.4 g. The single Group 3 animal that died during dosing on Day 1 was excluded from these calculations. Comparison of weight increase among the three Groups showed no significant difference using a one-way ANOVA analysis.
We initially examined the degree of dopaminergic neurodegeneration caused by MPTP administration by evaluating the levels of dopamine and its main metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in samples of brain striatum from control and MPTP treated mice. The results of this analysis are shown in Table 1 and summarized in Fig. 1. The control Group 1 (saline only) dosing regimen was used to determine the baseline levels for dopamine, and its two metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). For dose Group 2 (15 mg/kg MPTP), there was a 49.8% decrease in dopamine content of the brain striatum relative to the baseline levels (Group 1), from 99.2±20.1 ng/mg protein to 49.8±23.5 ng/mg protein. Likewise, dose Group 2 showed a 63.9% decrease in DOPAC from 23.1±7.1 ng/mg protein to 8.3±3.3 ng/mg protein, and a 29.1% decrease in HVA from 15.9±3.4 ng/mg protein to 11.3±3.7 ng/mg protein. For dose Group 3 (17 mg/kg) there was a 70.9% decrease in dopamine content of the brain striatum relative to the baseline levels (Group 1), from 99.2±20.1 ng/mg protein to 28.9±10.8 ng/mg protein. Likewise, dose Group 3 showed an 81.3% decrease in DOPAC from 23.1±7.1 ng/mg protein to 4.4±1.3 ng/mg protein, and a 47.8% decrease in HVA from 15.9±3.4 ng/mg protein to 8.3±2.1 ng/mg protein. Importantly, the measured decreases in the biogenic amine and its metabolites are consistent with values previously reported for a well-defined working MPTP-induced PD mouse model .
The degree of dopaminergic neurodegeneration caused by MPTP administration was evaluated by examining the levels of dopamine (A), DOPAC (B), and HVA (C). As a control, the effect of MPTP administration on noradrenaline levels (D) was also evaluated in the same samples. Results of striatum values from control and MPTP treated mice were analyzed by ANOVA followed by Tukey’s post-hoc test. Lowercase letters above the bars indicate the results of that analysis; values that share any letter in common are not significantly different (P ≥ 0.05), and values that do not share any letter in common are significantly different (P < 0.05).
As a control, we examined the effect of MPTP administration on the catecholamines, adrenaline and noradrenaline. The results of this analysis are shown in Table 1 and summarized in Fig. 1D. Adrenaline levels were undetectable in tissues from any of the animals examined, with the exception of one control animal (data not shown). However, noradrenaline was detectable, and there were no statistically significant differences between the noradrenaline levels in the brain striatum for any of the groups. This lack of change in the measured noradrenaline suggests the dissections were performed consistently.
To further evaluate the degree of dopaminergic neurodegeneration caused by MPTP administration we performed an immunohistochemical analysis of tyrosine hydroxylase in brain sections from control and MPTP treated mice. Images of a sample from a control (Group 1) animal and one from a high dose (Group 3) animal are shown in Fig. 2. In this experiment, immunofluorescence visualization shows a marked decrease in the number of dopamine neurons between the control group and the MPTP-treated groups. The fluorescent staining pattern of tyrosine hydroxylase shows the loss of cells in the striatum of an animal in dose Group 3 (Fig. 2B) compared with the striatum of animal from the control group (Fig. 2A). In addition, the staining on the left side of each panel shows that the dopamine neurons in the ventral tegmental area (VTA) are less affected by the MPTP than those nigral cells. The VTA neurons are more resistant and as such serve as a good control.
Tyrosine hydroxylase expression was evaluated by immunofluorescence staining of a brain section from a control untreated mouse (A) or a corresponding brain section from a mouse treated with 17 mg/kg MPTP (B).
We performed PET imaging studies of control and MPTP treated mice using the VMAT2 ligand [18F]-DTBZ (AV-133). As shown in Fig. 3A, a clear decrease in [18F]-DTBZ uptake can be seen in the striatum regions of brains from mice treated with 15 mg/kg and 17 mg/kg MPTP compared with a control (untreated) mouse. This loss of uptake suggests that the dopaminergic neurons in the striatum were successfully lesioned and that [18F]-DTBZ may be useful for imaging VMAT2 in the mouse brain. To correlate loss of dopaminergic neurons with decreased [18F]-DTBZ uptake, we performed an immunohistochemical analysis of tyrosine hydroxylase in brain sections from these mice (Fig 3B). In these animals, the staining pattern of tyrosine hydroxylase clearly shows the loss of cells in the striatum of treated with 15 mg/kg and 17 mg/kg MPTP compared with the striatum of the control animal.
A control male C57BL/6NCrl mouse and mice treated with 15 mg/kg MPTP or 17 mg/kg MPTP were imaged by PET using [18F]-DTBZ. (A) Shown are coronal brain slices depicting the uptake of [18F]-DTBZ corresponding to the anatomical localization of VMAT sites in the striatum. (B) Shown are coronal brain slices from the same animals depicting immunohistochemical visualization of tyrosine hydroxylase activity in dopaminergic neurons.
Quantitative analysis of the PET images from six animals is shown in Fig. 4. In this experiment, regions of interest (ROIs) for the striatum were identified in the PET images of two control animals in seven slices, and individual voxel values were measured within the ROIs for both left and right striatum. Afterwards, the minimum voxel value was normalized to 0 and the maximum voxel value was normalized to 1, and the mean voxel values in each of the seven slices were obtained. The mean and standard deviation of voxel values from all seven slices of each animal were then determined to obtain a relative voxel value. For comparison with striatum values, ROIs of the cerebellum were also measured in eleven image slices using circular regions of radius 10 voxels. As shown in Fig. 4A, the MPTP treated mice (m3 – m6) showed significantly lower signal intensities corresponding to decreased [18F]-DTBZ striatum uptake, compared with either control mouse m1 (P < 0.0001) or control mouse m2 (P < 0.0001). As a control, the [18F]-DTBZ uptake in the cerebellum was also examined. By one-way ANOVA, there was no significant difference when the control mice (m1 and m2) and the MPTP treated mice m4, m5, and m6 were compared (P = 0.639). However, m3 did show a lower background [18F]-DTBZ uptake (P < 0.0001) in the cerebellum when compared with any of the other mice by pair-wise Tukey’s post-hoc test.
Control male C57BL/6NCrl mice (m1 and m2) and mice treated with 15 mg/kg MPTP (m3 and m4) or 17 mg/kg MPTP (m5 and m6) were imaged by PET using [18F]-DTBZ. Normalized mean voxel values from regions of interest corresponding to each slice of striatum and cerebellum were obtained, and values shown are means±SD for all image slices from each animal. Results of striatum values from control and MPTP treated mice were analyzed by ANOVA followed by Tukey’s post-hoc test. Lowercase letters above the symbols indicate the results of that analysis; values that share any letter in common are not significantly different (P ≥ 0.05), and values that do not share any letter in common are significantly different (P < 0.05). In a similar fashion, results of cerebellum values from control and MPTP treated mice were analyzed by ANOVA followed by Tukey’s post-hoc test.
Parkinson’s disease is a progressive neurological disorder affecting as many as one million Americans. Several animal models have been developed to gain basic understanding about the mechanisms involved in the onset and progression of this progressive neurological disorder , . These include toxin, such as MPTP, induced animal models that cause selective depletion of dopamine producing neuronal cells . With the advances in the area of non-invasive imaging, novel radioactive ligands such as [11C]- and [18F]-DTBZ have been developed that bind to the neurotransmitter receptors with high selectivity and affinity. Radioligands such as these have emerged as potential tools capable of detecting the decline in dopaminergic activity in the affected regions of the brain.
The present study demonstrates the usefulness and efficacy of 18F-DTBZ analog as a radioligand for the study of dopaminergic loss in the MPTP induced PD mouse model. The [18F]-DTBZ analog is a PET tracer with a relatively longer half-life compared with the currently available radiopharmaceuticals and shows high affinity binding to the vesicular monoamine transporter (VMAT2), which plays an important role in the transfer of monoamines, in particular, neurotransmitters, from cytoplasm into synaptic vesicles. This in turn provides a good correlation between binding of 18F-DTBZ analog and innervation of the striatum by dopamine-rich neurons. We substantiated the use of functional imaging modality with classical methods employed to assess the changes in the dopaminergic activity.
In addition to the brain, VMAT2 has been found to be expressed in pancreatic beta cells together with insulin. This co-localization has allowed assessment of beta cell mass by non-invasive imaging using [11C]- and [18F]-DTBZ in models of diabetes –. One limiting factor, however, for quantifying beta cell mass has been non-specific uptake of radioligand in the pancreas . Recent work has suggested that sigma-1 and sigma-2 receptors not associated with beta cells are responsible for low affinity background binding in pancreas . This and future progress in understanding of radioligand function in pancreas as well as VMAT2 biology should facilitate the application of [18F]-DTBZ for PET imaging of disease progression in patients with diabetes.
Our findings demonstrate the considerable loss of dopamine-producing neurons in the mouse striatum as evidenced by the biochemical analysis of different monogenic amines in the brain tissue samples of MPTP treated animals. A significant decrease in the content of dopamine and its metabolic byproducts is observed in the animals that demonstrated characteristic lesions following treatment with MPTP neurotoxin vs. control group. In addition, no statistically significant differences were evident in the levels of adrenaline and noradrenaline, which served as control biomarkers in treated and untreated groups. Our results are consistent with previous studies characterizing dopaminergic depletion in mice following treatment with MPTP –. In addition to these findings, tyrosine hydroxylase levels also correlate with neuronal degeneration in the striatum of MPTP treated mice when compared with untreated mice , .
Non-invasive imaging techniques offer several advantages over the conventional methods, including the longitudinal follow-up of the animals throughout the study without euthanasia and detection of alterations in the neuronal system in presymptomatic animals at an initial stage. We therefore, confirmed our previous results by imaging animals using a PET scanner. We observed reduced uptake of the 18F-radiolabeled DTBZ analog in the mouse striatum in the treated vs. control groups. Our data is consistent with published reports studying the evolution of dopaminergic reduction in MPTP-induced PD in monkeys , and with the clinical studies using different radioactive PET imaging molecules in healthy volunteers  and PD patients . Furthermore, the ventral tegmental area (VTA) was found to be weakly stained as compared with the striatum. This difference can be attributed to the fact that dopaminergic neurons present in VTA are less prone to the MPTP-induced lesions.
A major issue with small animals such as mice is the spatial resolution of PET imaging. In PET imaging, the emitted positron travels some distance from the decay before annihilation with an electron resulting in the emission of two 511 KeV gamma rays. The random nature of this travel between the positron and gamma ray points of origin has some impact on the lower limit of spatial resolution obtainable from a scanner. For 18F, the travel range of the emitted positron from the decay (Emax = 0.633 MeV) is approximately 0.6 mm in water ; phantom studies indicated that 1 mm sized objects can be resolved using 18F labeled tracers and appropriate scanner technology. Another factor is the partial volume effect, which must be considered when performing manual analysis (e.g., identifying the regions of interest). However, data had the advantage of registered CT data with a resolution of 0.1 mm3. This high-resolution CT data allowed the PET data to be registered (and resliced) to a standard atlas to identify the brain structures of interest. Thus, in our analysis the volume of the sampled area was almost 10 mm3 in each image set, which should minimize any potential partial volume effects on the quantitative results.
In conclusion, our approach should provide the basis to use 18F-labeled DTBZ analogs as potent radiotracers to follow up the process of PD involving dopamine dysfunction by positron emission tomography. This may help in the advent of novel diagnostic and therapeutic agents required for both the early assessment and treatment of this neurodegenerative disorder.
We acknowledge the expert technical assistance of Mr. Chris Vascoe at the Biomedical Research Institute of Northwest Louisiana for producing the [18F]-DTBZ radiotracer (AV133) radiotracer.
Conceived and designed the experiments: JST JMM SJL ADP. Performed the experiments: SB LTM EAO KHT SJL TT JMM. Analyzed the data: JST SB KHT SJL JMM ADP. Contributed reagents/materials/analysis tools: JST LTM TT ADP. Wrote the paper: JST SB EAO KHT SJL JMM ADP.
- 1. Horowitz MP, Greenamyre JT (2010) Gene-environment interactions in Parkinson’s disease: the importance of animal modeling. Clin Pharmacol Ther. 88: 467.474MP HorowitzJT Greenamyre2010Gene-environment interactions in Parkinson’s disease: the importance of animal modeling. Clin Pharmacol Ther.88467474
- 2. Meredith GE, Sonsalla PK, Chesselet MF (2008) Animal models of Parkinson’s disease progression. Acta Neuropathol. 115: 385.398GE MeredithPK SonsallaMF Chesselet2008Animal models of Parkinson’s disease progression. Acta Neuropathol.115385398
- 3. Schober A (2004) Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res. 318: 215.224A. Schober2004Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res.318215224
- 4. Honer M, Hengerer B, Blagoev M, Hintermann S, Waldmeier P, et al. (2006) Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice. Nucl Med Biol. 33: 607.614M. HonerB. HengererM. BlagoevS. HintermannP. Waldmeier2006Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice. Nucl Med Biol.33607614
- 5. Frey KA, Koeppe RA, Kilbourn MR (2001) Imaging the vesicular monoamine transporter. Adv Neurol. 86: 237.247KA FreyRA KoeppeMR Kilbourn2001Imaging the vesicular monoamine transporter. Adv Neurol.86237247
- 6. Goswami R, Ponde DE, Kung MP, Hou C, Kilbourn MR, et al. (2006) Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol. 33: 685.694R. GoswamiDE PondeMP KungC. HouMR Kilbourn2006Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol.33685694
- 7. Harris PE, Ferrara C, Barba P, Polito T, Freeby M, et al. (2008) VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med. 86: 5.16PE HarrisC. FerraraP. BarbaT. PolitoM. Freeby2008VMAT2 gene expression and function as it applies to imaging beta-cell mass. J Mol Med.86516
- 8. Simpson NR, Souza F, Witkowski P, Maffei A, Raffo A, et al. (2006) Visualizing pancreatic beta-cell mass with [11C]DTBZ. 2006. Nucl Med Biol. 33: 855.864NR SimpsonF. SouzaP. WitkowskiA. MaffeiA. Raffo2006Visualizing pancreatic beta-cell mass with [11C]DTBZ. 2006. Nucl Med Biol.33855864
- 9. Vergo S, Johansen JL, Leist M, Lotharius J (2007) Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res. 1185: 18.32S. VergoJL JohansenM. LeistJ. Lotharius2007Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res.11851832
- 10. Henry JP, Scherman D (1989) Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem Pharmacol. 38: 2395.2404JP HenryD. Scherman1989Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem Pharmacol.3823952404
- 11. Hoffman BJ, Hansson SR, Mezey E, Palkovits M (1998) Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. 1998. Front Neuroendocrinol. 19: 187.231BJ HoffmanSR HanssonE. MezeyM. Palkovits1998Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. 1998. Front Neuroendocrinol.19187231
- 12. Taylor TN, Caudle WM, Miller GW (2011) VMAT2-Deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson’s disease. Parkinsons Dis. 2011: 124165.TN TaylorWM CaudleGW Miller2011VMAT2-Deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson’s disease. Parkinsons Dis.2011124165
- 13. Bohnen NI, Albin RL, Koeppe RA, Wernette K, Kilbourn MR, et al. (2006) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 26: 1198.1212NI BohnenRL AlbinRA KoeppeK. WernetteMR Kilbourn2006Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab.2611981212
- 14. Kung MP, Hou C, Goswami R, Ponde DE, Kilbourn MR, et al. (2007) Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol. 34: 239.246MP KungC. HouR. GoswamiDE PondeMR Kilbourn2007Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol.34239246
- 15. Lin KJ, Weng YH, Wey SP, Hsiao IT, Lu CS, et al. (2010) Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med. 51: 1480.1485KJ LinYH WengSP WeyIT HsiaoCS Lu2010Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent. J Nucl Med.5114801485
- 16. Wang JL, Oya S, Parhi AK, Lieberman BP, Ploessl K, et al. (2010) In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson’s disease. Nucl Med Biol. 37: 479.486JL WangS. OyaAK ParhiBP LiebermanK. Ploessl2010In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson’s disease. Nucl Med Biol.37479486
- 17. Donzanti BA, Yamamoto BK (1998) A rapid and simple HPLC microassay for biogenic amines in discrete brain regions. Pharmacol Biochem Behav. 30: 795.799BA DonzantiBK Yamamoto1998A rapid and simple HPLC microassay for biogenic amines in discrete brain regions. Pharmacol Biochem Behav.30795799
- 18. Zhu L, Liu Y, Plossl K, Lieberman B, Liu J, et al. (2010) An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2. Nucl Med Biol. 37: 133.141L. ZhuY. LiuK. PlosslB. LiebermanJ. Liu2010An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2. Nucl Med Biol.37133141
- 19. Franklin KBJ, Paxinos G (2008) The Mouse Brain in Stereotaxic Coordinates (3rd edition). Academic Press, Boston. KBJ FranklinG. Paxinos2008The Mouse Brain in Stereotaxic Coordinates (3rd edition).Academic Press, Boston
- 20. Heise CE, Teo ZC, Wallace BA, Ashkan K, Benabid AL, et al. (2005) Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients. Anat Embryol (Berl). 210: 287.302CE HeiseZC TeoBA WallaceK. AshkanAL Benabid2005Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients. Anat Embryol (Berl).210287302
- 21. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, et al. (2001) The Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. 2001. J Neurochem. 76: 1265.1274S. PrzedborskiV. Jackson-LewisAB NainiM. JakowecG. Petzinger2001The Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. 2001. J Neurochem.7612651274
- 22. Hattori N, Sato S (2007) Animal models of Parkinson’s disease: similarities and differences between the disease and models. Neuropathology. 27: 479.483N. HattoriS. Sato2007Animal models of Parkinson’s disease: similarities and differences between the disease and models. Neuropathology.27479483
- 23. Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson’s disease. 2005. Brain Res Mol Brain Res. 134: 57.66RJ SmeyneV. Jackson-Lewis2005The MPTP model of Parkinson’s disease. 2005. Brain Res Mol Brain Res.1345766
- 24. Kung MP, Hou C, Lieberman BP, Oya S, Ponde DE, et al. (2008) In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med. 49: 1171.1176MP KungC. HouBP LiebermanS. OyaDE Ponde2008In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus. J Nucl Med.4911711176
- 25. Eriksson O, Jahan M, Johnström P, Korsgren O, Sundin A, et al. (2010) In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol. 37: 357.363O. ErikssonM. JahanP. JohnströmO. KorsgrenA. Sundin2010In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol.37357363
- 26. Singhal T, Ding YS, Weinzimmer D, Normandin MD, Labaree D, et al. (2011) Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes. Mol Imaging Biol. 13: 973.984T. SinghalYS DingD. WeinzimmerMD NormandinD. Labaree2011Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes. Mol Imaging Biol.13973984
- 27. Veluthakal R, Harris P (2010) In vivo beta-cell imaging with VMAT 2 ligands–current state-of-the-art and future perspective. Curr Pharm Des. 16: 1568.1581R. VeluthakalP. Harris2010In vivo beta-cell imaging with VMAT 2 ligands–current state-of-the-art and future perspective. Curr Pharm Des.1615681581
- 28. Tsao HH, Skovronsky DM, Lin KJ, Yen TC, Wey SP, et al. (2011) Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas. Nucl Med Biol. 38: 1029.1034HH TsaoDM SkovronskyKJ LinTC YenSP Wey2011Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas. Nucl Med Biol.3810291034
- 29. Balkowiec-Iskra E, Kurkowska-Jastrzebska I, Joniec I, Ciesielska A, Muszynska A, et al. (2007) MPTP-induced central dopamine depletion exacerbates experimental autoimmune encephalomyelitis (EAE) in C57BL mice. 2007. Inflamm Res. 56: 311.317E. Balkowiec-IskraI. Kurkowska-JastrzebskaI. JoniecA. CiesielskaA. Muszynska2007MPTP-induced central dopamine depletion exacerbates experimental autoimmune encephalomyelitis (EAE) in C57BL mice. 2007. Inflamm Res.56311317
- 30. Youdim MB, Grunblatt E, Mandel S (2007) The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. J Neural Transm. 114: 205.209MB YoudimE. GrunblattS. Mandel2007The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. J Neural Transm.114205209
- 31. Selley ML (2005) Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res. 1037: 1.6ML Selley2005Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res.103716
- 32. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, et al. (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci USA. 95: 7659.7663J. AraS. PrzedborskiAB NainiV. Jackson-LewisRR Trifiletti1998Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci USA.9576597663
- 33. Jakowec MW, Nixon K, Hogg E, McNeill T, Petzinger GM (2004) Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. J Neurosci Res. 76: 539.550MW JakowecK. NixonE. HoggT. McNeillGM Petzinger2004Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. J Neurosci Res.76539550
- 34. Blesa J, Juri C, Collantes M, Penuelas I, Prieto E, et al. (2010) Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study. Neurobiol Dis. 38: 456.463J. BlesaC. JuriM. CollantesI. PenuelasE. Prieto2010Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study. Neurobiol Dis.38456463
- 35. Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, et al. (2010) In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med. 51: 223.228N. OkamuraVL VillemagneJ. DragoS. PejoskaRK Dhamija2010In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med.51223228
- 36. Partridge M, Spinelli A, Ryder W, Hindorf C (2006) The effect of β+ energy on performance of a small animal PET camera. Nucl Instrum Methods A 568: 933.936M. PartridgeA. SpinelliW. RyderC. Hindorf2006The effect of β+ energy on performance of a small animal PET camera.Nucl Instrum Methods A568933936